H
9.10
0.04 (0.44%)
| Penutupan Terdahulu | 9.06 |
| Jumlah Dagangan | 21,428,085 |
| Harga / Pendapatan (P/E Ke hadapan) | 15.10 |
| Harga / Jualan (P/S) | 2.71 |
| Harga / Buku (P/B) | 1.84 |
| Julat 52 Minggu | |
| Hasil Dividen (DY TTM) | 2.14% |
| Margin Keuntungan | 12.84% |
| Margin Operasi (TTM) | 22.87% |
| EPS Cair (TTM) | 0.420 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -0.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 32.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 63.41% |
| Nisbah Semasa (MRQ) | 0.980 |
| Aliran Tunai Operasi (OCF TTM) | 2.30 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.43 B |
| Pulangan Atas Aset (ROA TTM) | 4.55% |
| Pulangan Atas Ekuiti (ROE TTM) | 8.95% |
Sentimen Berita
Negatif
AISkor Stockmoo
| Nilai 38% | 0.3 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.3 |
| Masa 38% | -1.9 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | -1.0 |
| Sentimen 25% | -0.9 |
| Konsensus Penganalisis info | 0.0 |
| Sentimen Berita info | -3.1 |
| Wang Pintar | NA |
| Aktiviti Orang Dalam info | NA |
| Aliran Institusi info | NA |
| Persekitaran | ×1.15 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -4.0% |
| Persetujuan Tonggak | ×1.14 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 4.8 |
| Skor Akhir | -1.10 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Haleon plc | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| HLN | - | 2.14% | - | 1.84 |
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
| TEVA | - | - | - | 6.23 |
| ZTS | - | 2.81% | - | 10.19 |
| HIMS | - | - | - | 18.72 |
|
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 0.02% |
| % Dimiliki oleh Institusi | 12.72% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2026 | Yahoo Finance |
Haleon (LSE:HLN) Stock Fair Value Falls After Guidance Cut And Mixed Analyst Revisions
Haleon’s analyst fair value estimate has changed, with the modelled price target moving from £4.18 to £3.76. This revision appears alongside a more mixed analyst narrative, where some research teams highlight execution risks and softer growth visibility, while others still point to the resilience… |
| 05 Nov 2026 | Yahoo Finance |
Does Reduced Growth Guidance Change The Bull Case For Haleon (LSE:HLN)?
Haleon has started a share repurchase programme authorised at its April 2026 AGM, allowing buybacks of up to 890,000,000 shares, or about 10% of issued capital, with flexibility to hold shares in treasury, use them for incentives or cancel them before the authority expires in mid 2027. The business… |
| 04 Nov 2026 | Yahoo Finance |
Haleon margin reset and weak sales beyond oral care prompt Jefferies downgrade to 'hold'
Haleon PLC (LSE:HLN, NYSE:HLN), the consumer health group behind Sensodyne and Centrum, has been downgraded by Jefferies to 'hold' from 'buy', saying the company needs lower prices and greater marketing investment to revive sales growth outside Oral Health. It cut its price target by 20% to… |
| 02 Nov 2026 | Yahoo Finance |
Goldman Sachs adds 2 stocks to European Conviction List
Investing.com -- Goldman Sachs added Deutsche Bank and Carlsberg to its European Conviction List in its November update, removing HSBC, Haleon and CTP. |
| 01 Nov 2026 | Yahoo Finance |
Haleon And 2 British AI Healthcare Stocks To Watch
Corporate investment in artificial intelligence has reached hundreds of billions of dollars, and some global healthcare groups are already reporting AI linked benefits in earnings. That shift in spending puts a spotlight on UK healthcare AI stocks that could benefit if hospitals and drug makers… |
| 30 Oct 2026 | Yahoo Finance |
Haleon faces calls for a reset as brokers question growth outlook
Haleon PLC (LSE:HLN, NYSE:HLN) received a Deutsche Bank upgrade despite a target cut, while RBC lowered its target and JPMorgan remained cautious after the group's third-quarter miss and guidance warning. Deutsche Bank moved from 'sell' to 'hold', RBC retained 'sector perform', and JPMorgan… |
| 30 Oct 2026 | Yahoo Finance |
UK Stock Market Today: FTSE 100 Futures Edge Up On OBR Debt Outlook
The Morning Bull - UK Market Morning Update Friday, 30 Oct 2026 UK stocks look set for a slightly positive open, with FTSE 100 futures barely higher and risk appetite shaped mainly by the latest UK fiscal outlook. The Office for Budget Responsibility's new projections are the clear reference point.… |
| 29 Oct 2026 | Yahoo Finance |
Haleon Catches a Cold at the Worst Possible Time
The Sensodyne maker plunged after weak cold-and-flu demand, a Chinese import disruption and softer consumer spending forced another cut to its growth outlook. |
| 29 Oct 2026 | Yahoo Finance |
Haleon Sinks 14% on Growth Downgrade Despite £500 Million Buyback: “Q3 Was Below Our Expectations”
Key TakeawaysHaleon shares fell 14% today after it cut its 2026 organic revenue growth outlook to around 2. 5%, from 3%-5%. |
| 29 Oct 2026 | Yahoo Finance |
Haleon shares plunge 14% after £500 million buyback launch - UPDATE
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell as much as 14% on Thursday, touching an intraday low of 321p, despite the consumer healthcare group launching a £500 million share buyback programme. The programme, announced alongside Haleon’s third-quarter trading update, will run until no… |
| 29 Oct 2026 | Yahoo Finance |
Haleon shares hit three-week low after growth downgrade, £500 million buyback
Investing.com -- Haleon (LON:HLN) shares fell sharply on Thursday, hitting a three-week low, after the consumer healthcare group cut its full-year organic revenue growth outlook following weaker-than-expected third-quarter trading, despite announcing a further £500 million share buyback. |
| 29 Oct 2026 | Yahoo Finance |
What Haleon (HLN) Said on Its Q3 Earnings Call
Haleon (NYSE:HLN) said its third-quarter performance fell below expectations, citing weaker-than-anticipated North American growth, a softer cough, cold and flu season, a Chinese classification issue affecting Centrum, and continued challenging consumer conditions in Europe. Chief Executive Officer… |
| 29 Oct 2026 | Yahoo Finance |
ASAIY or HLN: Which Is the Better Value Stock Right Now?
ASAIY vs. HLN: Which Stock Is the Better Value Option? |
| 28 Oct 2026 | Yahoo Finance |
Haleon (LSE:HLN) Has Investors Asking A Bigger Question
Haleon (LSE:HLN) has drawn fresh attention after appointing Deep Malde as Head of Expert Marketing & Transformation, a move that brings experienced consumer health and brand leadership closer to its extensive over the counter portfolio. The latest executive hire comes as Haleon’s share price has… |
| Papar semua | ||
| Hasil Dividen (DY TTM) | 2.14% |
| Purata Hasil Dividen 3T | 1.36% |
| Nisbah Pembayaran | 39.30% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 25 Apr 2025 | 27 Feb 2025 | 05 Jun 2025 | 0.11661 Tunai |
| 16 Aug 2024 | 01 Aug 2024 | 19 Sep 2024 | 0.051416 Tunai |
| 14 Mar 2024 | 29 Feb 2024 | 16 May 2024 | 0.1063524 Tunai |
| 24 Aug 2023 | 02 Aug 2023 | 05 Oct 2023 | 0.0459936 Tunai |
| 16 Mar 2023 | 02 Mar 2023 | 27 Apr 2023 | 0.0577344 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2025 | 0.117 | 1 | 1.15 |
| 2024 | 0.158 | 2 | 1.65 |
| 2023 | 0.104 | 2 | 1.26 |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |